Survival Analysis of Untreated Patients With Non-Small-Cell Lung Cancer

Vrdoljak, Eduard; Mise, Kazuyuki; Sapunar, Damir; Rozga, Ante; Marušić, Matko

doi:10.1378/chest.106.6.1797

Cited by 53 publications

(21 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have reported outcomes after curative intent RT for patients with early stage NSCLC [6], but few have also assessed patients treated palliatively and those not treated at all. Patients who are untreated are of particular importance, as they represent approximately one-third of inoperable early stage patients, are more likely to be older and of racial minority status, and rarely survive more than a few years [1,10].…”

Section: Introductionmentioning

confidence: 99%

Inoperable early stage non-small cell lung cancer: Comorbidity, patterns of care and survival

et al. 2011

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Inoperable early stage non-small cell lung cancer: Comorbidity, patterns of care and survival

et al. 2011

View full text Add to dashboard Cite

“…The 5-year survival rate has been low (Damhuis and Schutte 1996;Fry et al 1999;Naruke et al 2001;Non-Small Cell Lung Cancer Collaborative Group 1995;Vrdoljak et al 1994) in spite of the progress in diagnosis and therapeutic intervention. Lung cancer development and progression are thought to occur through a complex, multistep process, including oncogenic activation and mutation or loss of tumor suppressor genes (Yokota and Kohno 2004), although molecular bases for lung carcinogenesis remain to be elucidated.…”

Section: Introductionmentioning

confidence: 99%

Cancer-associated loss of TARSH gene expression in human primary lung cancer

Terauchi

Shimada

Uekawa

et al. 2005

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…• Treatment with chemotherapy prolongs survival and improves quality of life in metastatic lung cancer; untreated patients live on average 4-6 months [49], whereas median survival of 9 months to a year has been reported in multiple recent treatment trials [9][10][11]. These benefits were proven prospectively in the elderly-specific phase III ELVIS trial [8••].…”

Section: Treatment Of Incurable Locally Advanced and Metastatic Diseasementioning

confidence: 99%

NSCLC in the Elderly—The Legacy of Therapeutic Neglect

Weiss

Langer

2009

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Although the majority of patients diagnosed with non-small cell lung cancer (NSCLC) are elderly, most clinical trials available to guide care either exclude the elderly or underrepresent them. This disregard for the elderly lung cancer patient extends to the clinical realm, where the elderly with lung cancer are less likely to be treated with either curative, or life-extending, palliative therapy. Few elderly-specific phase III trials are available to provide level I evidence. However, subgroup analyses and meta-analyses of large clinical trials enrolling substantial numbers of elderly patients are available to guide care, although these are potentially subject to selection bias. These trials suggest that the fit elderly derive as much benefit from surgery, chemoradiation, and platinum-based doublet chemotherapy as younger patients across all stages of disease. For the less fit elderly, in particular those with limited performance status or significant co-morbidities, less aggressive regimens are likely preferred, with the goal of extending life and delaying or suppressing cancer symptoms. Ultimately, care decisions must incorporate knowledge of the literature, evaluation of the patient's clinical characteristics, and patient priorities. The elderly should be aggressively recruited to clinical trials, including elderly-specific trials and trials of patients with limited performance status and co-morbidities.

show abstract

Survival Analysis of Untreated Patients With Non-Small-Cell Lung Cancer

Cited by 53 publications

References 4 publications

Inoperable early stage non-small cell lung cancer: Comorbidity, patterns of care and survival

Inoperable early stage non-small cell lung cancer: Comorbidity, patterns of care and survival

Cancer-associated loss of TARSH gene expression in human primary lung cancer

NSCLC in the Elderly—The Legacy of Therapeutic Neglect

Contact Info

Product

Resources

About